Bayer's Ohio Plant Offers Tariff Relief as JPMorgan Cautions on Q3 Hopes

Bayer plans a $2.2 billion Ohio pharma complex to cut US tariff exposure, while JPMorgan warns Q3 expectations may be too high.

Bayer's push to anchor more of its pharmaceutical production on American soil has a clear financial rationale behind it: avoiding the steepest tier of US import duties. Under Section 232 rules, tariffs on imported branded medicines can reach as high as 100 percent, but companies that commit to domestic manufacturing see that rate drop to 20 percent. With special levies already in force on certain patented imports and additional charges on generic drugs slated from 2028, the incentive to build inside the US market has become considerably harder to ignore.

That calculus sits behind Bayer's planned complex in New Albany, Ohio, a project carrying a $2.2 billion price tag on a site of roughly 200 acres. The Leverkusen-based group expects the build-out to generate 1,500 construction jobs, with around 600 highly qualified permanent positions once operations are running.

A Long Wait for Returns

The timeline is anything but short. Production of the first active ingredients — aimed at oncology therapies as well as heart and kidney treatments — is scheduled to begin in 2031. The final module for finished medicines is targeted for 2034. Until then, the investment will tie up liquid capital for years before a single product leaves the facility.

Bayer is hardly starting from scratch in the US. Over the past five years, the company has directed more than $7 billion into American pharmaceutical research, development and manufacturing sites. CEO Bill Anderson has repeatedly described the country as an indispensable industrial base and a central hub of innovation.

JPMorgan Flags Stretched Expectations

While the Ohio project addresses trade exposure, near-term earnings are drawing a more cautious read from analysts. JPMorgan's Richard Vosser kept his "Overweight" rating on the stock with a price target of 61 euros, but cautioned that early market expectations for the third quarter may be set too high. His main concern: timing effects in the agricultural business.

The measured tone from the analyst house lands against a market mood that is already strained. Bayer shares closed Friday at 45.02 euros, a decline of 10 percent over the week. Even so, the stock has climbed 22 percent since the start of the year and trades 4.5 percent above its 200-day moving average of 43.09 euros.

Legal Clouds Refuse to Lift

Press reports point to litigation, rather than operational worries alone, as the dominant weight on the share price. In Missouri, another Roundup trial has opened, with three plaintiffs alleging the company failed to conduct adequate testing. The case falls outside the proposed collective settlement and is proceeding despite a US Supreme Court ruling on warning labels. Bayer rejects the allegations. Separately, a court roughly a week ago declined a motion to dismiss patent lawsuits tied to mRNA technology.

Those legal entanglements continue to overshadow the company's broader strategic overhaul. For investors, uncertainty over the financial fallout from the US cases remains the single biggest unknown.

Financing and Portfolio Moves Continue

Bayer is pressing ahead on other fronts regardless. The group raised 2 billion euros through hybrid bonds placed on the capital market. It also divested the cancer drug Stivarga, with rights going to Grünenthal for up to 375 million euros. Alongside these moves, Dr. Christoph Koenen stepped into the role of Chief Medical Officer for the pharmaceutical division.

The balancing act for management — strict budget discipline versus the costly shield against tariff barriers — remains a demanding one. Should the company strengthen supply-chain resilience without letting costs spiral, its US footprint could eventually serve as a stabilizing anchor.

Concrete answers arrive on November 3, 2026, when Bayer publishes its quarterly statement for the third quarter. Only then will the actual strain on the agricultural division and the group's financial trajectory become clear — and only then will it be possible to judge whether the analysts' cautious stance was warranted.